Full-Time
Financial Counselor
Roswell Park Comprehensive Cancer Center
1,001-5,000 employees
Comprehensive cancer research and treatment center
Compensation Overview
$53.4k/yr
United States
In Person
Associate's
 Accounting (1) |
|---|
Get referred to Roswell Park Comprehensive Cancer Center
See people who can refer or advise you
- A high school diploma or High School Equivalency diploma and three years of full-time experience in authorization and follow-up procedures or a related field.
- A high school diploma or High School Equivalency diploma and two years of full-time experience in Financial Clearance and/or Patient Access within the Financial Clearance Department at Roswell Park Comprehensive Cancer Center.
- An Associate's degree and three years of full-time experience in authorization and follow-up procedures or related fields.
- A high school diploma or High School Equivalency diploma and five years of full-time experience in authorization and follow-up procedures or related fields.
- A high school diploma or High School Equivalency diploma and four years of full-time experience in Financial Clearance and/or Patient Access within the Financial Clearance Department at Roswell Park Comprehensive Cancer Center.
- Degrees must be conferred by an accredited school, college, or university, or by an institution recognized by Roswell Park Comprehensive Cancer Center and/or Health Research Incorporated as adhering to acceptable educational standards.
- Strong customer service skills and a solid understanding of healthcare billing and insurance.
- The ability to communicate clearly and compassionately with patients from diverse backgrounds.
- The ability to explain complex financial and insurance concepts in a simple way.
- Strong problem-solving skills and attention to detail.
- The ability to manage sensitive conversations with professionalism and empathy.
- The ability to work well with cross-functional teams and build strong relationships.
- The ability to stay organized and balance multiple priorities.
- Counsel patients on insurance coverage, benefits, out-of-pocket costs, and payment options.
- Help patients apply for Medicaid or other coverage through the New York State Marketplace.
- Review accounts and resolve complex billing or insurance issues, including coordination of benefits.
- Support insurance verification and authorization processes.
- Provide cost estimates for self-pay patients and collect required deposits.
- Meet with patients in person or over the phone across a variety of care settings.
- Collaborate with Patient Access, Billing, Social Work, and Clinical staff.
- Serve as a key point of contact for patient financial questions and concerns.
- Provide guidance, training, and support to Financial Clearance Representatives and Payment Services team members.
Roswell Park Comprehensive Cancer Center brings together laboratory research, clinical care, and education in a multidisciplinary environment to advance cancer treatment. Researchers and clinicians work side by side to translate laboratory findings into patient therapies and contribute to ongoing trials, with historical breakthroughs in chemotherapy, photodynamic therapy, and PSA testing. It differentiates itself as the world’s first cancer-focused laboratory, operates as a public benefit corporation owned by New York State, and relies on grants and donations through affiliated nonprofits. The center’s goal is to conquer cancer by coordinating research, clinical care, and education to improve patient outcomes and scientific knowledge.
Company Size
1,001-5,000
Company Stage
Grant
Total Funding
$71.1M
Headquarters
Buffalo, New York
Founded
1898
Get referred to Roswell Park Comprehensive Cancer Center
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 2026 Hyundai Hope on Wheels gave Roswell Park $100,000 for pediatric AML CAR T research.
- Roswell Park secured FY25 CDMRP funding on August 10, 2026 for mutant p53 breast cancer work.
- August 2026 and July 2026 announcements show strong external demand for Roswell Park scientific expertise.
What critics are saying
- The Grand'Maison whistleblower case keeps patient-safety allegations and retaliation claims active through 2026.
- Independent Health’s Medicare Advantage dispute threatens out-of-network access for patients starting January 2026.
- Funding dependence on grants, donations, and state budgets exposes Roswell Park to abrupt research slowdowns.
What makes Roswell Park Comprehensive Cancer Center unique
- Roswell Park remains Upstate New York’s only NCI-designated comprehensive cancer center in 2026.
- Its 4,000-plus staff span research, clinical care, and education under one Buffalo campus.
- The 2026 Burjeel and Sethera collaborations extend Roswell Park’s protocols internationally and into novel drug discovery.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 2%Roswell Park's recognition: implications for cancer care and research. August 15, 2026 Recently, Roswell Park Comprehensive Cancer Center was honored by Forbes as one of the best employers for women and one of the best in-state employers. This prestigious recognition highlights not only the quality of the workplace environment but also the potential impact on patient care and cancer research. In a field as complex and challenging as oncology, the well-being of healthcare professionals can directly influence the quality of care that patients receive. In this blog post, Cure Cancer With AI will explore the significance of such recognition for cancer patients and the broader implications for the research community. What happened. Forbes evaluated numerous organizations to compile its list of top workplaces, focusing on employee satisfaction, support, and overall happiness. Roswell Park's inclusion in these lists signifies a commitment to cultivating a positive work culture, which is paramount in a high-stress environment like cancer care. A supportive workplace can lead to better collaboration among staff, improved patient interactions, and ultimately, enhanced treatment outcomes. Background: the importance of employee satisfaction in cancer care. The connection between employee satisfaction and patient care is well-documented. When healthcare professionals feel valued and supported, they are more likely to go above and beyond for their patients. In the context of cancer treatment, this can translate to greater attentiveness, empathy, and a holistic approach to patient care. For patients and their families, knowing that the staff at a cancer center is content can foster trust and confidence in the care they will receive. Roswell Park's achievement serves as a reminder that the overall atmosphere within a healthcare facility can significantly affect the patient experience. A positive work culture not only enhances staff morale but also contributes to a more patient-centered approach to care. When healthcare teams work cohesively and supportively, it can lead to better health outcomes, particularly in oncology, where treatment regimens are often complex and multifaceted. How AI fits into cancer research and the path toward better treatments. Artificial intelligence (AI) and machine learning are revolutionizing cancer research and treatment, offering unprecedented opportunities to enhance patient care. While Roswell Park's recognition focuses on employee satisfaction, it also highlights the importance of an environment conducive to innovation. The integration of AI in oncology can lead to more effective diagnostics, personalized treatment plans, and accelerated drug discovery processes. The role of AI in diagnostics. AI technologies are being used to analyze medical imaging and pathology reports more efficiently than traditional methods. By identifying patterns that humans might miss, AI can assist healthcare professionals in making quicker and more accurate diagnoses. This rapid identification is crucial in oncology, where early detection can significantly influence treatment efficacy. Machine learning in drug discovery. In drug discovery, machine learning algorithms can analyze vast datasets to identify potential therapeutic targets and predict how different compounds might behave in the human body. This approach not only speeds up the development of new cancer treatments but also helps researchers understand which patients are likely to benefit from specific therapies, paving the way for precision oncology. AI-Driven patient management. AI is also transforming how healthcare systems manage cancer patients. From tracking treatment progress to predicting patient outcomes, AI tools can enhance the overall patient experience. For instance, predictive analytics can help healthcare providers identify which patients might need additional support, ensuring that care is tailored to individual needs. What patients and readers should know. For cancer patients and their families, understanding the implications of workplace satisfaction at cancer centers like Roswell Park is vital. A supportive environment for healthcare providers can lead to improved patient care, which is essential in the context of cancer treatment. As patients navigate their journeys, knowing that they are being cared for by satisfied and engaged professionals can offer peace of mind. Furthermore, staying informed about advancements in cancer research and the role of AI can empower patients and their families. Resources like curecancerwithai.com provide a centralized platform for exploring how artificial intelligence is being used in oncology, keeping patients and advocates updated on the latest news and developments in cancer research. This knowledge can help families make more informed decisions about their care and understand the potential benefits of emerging treatments. Conclusion. The recognition of Roswell Park as one of the best employers underscores the importance of a supportive workplace in the field of oncology. As cancer treatment continues to evolve with the integration of artificial intelligence and machine learning, the implications for patient care are profound. By fostering an environment where healthcare professionals feel valued, Cure Cancer With AI can ensure that patients receive the highest standard of care. For those interested in learning more about how AI is transforming cancer research and treatment, curecancerwithai.com offers valuable insights and resources to stay informed.
Roswell Park named to Best Employers for Women and Best In-State Employers lists. Cancer center ranked on national lists by Forbes. Highlights * Women's list based on surveys from more than 146,000 women * Roswell Park ranked as top healthcare organization in state employers list * Also recognized as one of America's Best Employers for Company Culture Newswise - BUFFALO, N.Y. - Roswell Park Comprehensive Cancer Center has been named by Forbes to its lists of America's Best Employers for Women and America's Best In-State Employers. Working with market research firm Statista to rank the companies, Forbes announced both lists this month. For its Best Employers for Women list, Forbes and Statista surveyed more than 146,000 women working for companies that employ at least 1,000 people in the United States. Participants were asked to rate their current employers in areas such as pay equity, career development, parental leave, work-life balance, benefits for childcare or eldercare, and the company's handling of incidents related to sexual misconduct or discrimination. Statista also researched the percentage of women in executive and board positions at each company. Roswell Park is the only Western New York healthcare organization on the list of 700 companies. Roswell Park was also recognized on Forbes' Best Employers by State listing, ranked as the top healthcare organization in New York and in the top 15 among overall employers. This is the fifth consecutive year that Roswell Park has made the list. For it, Statista surveyed more than 245,000 employees who work for a company of at least 500 people in the country. Survey respondents were asked how likely they were to recommend their employer on a scale of zero to 10 on topics such as wages and benefits, management style, company reputation, flexibility and career advancement. Earlier this year, Roswell Park was named to Forbes list of America's Best Employers for Company Culture and Newsweek's list of World's Best Specialized Hospitals. See the full list of America's Best Employers for Women here and America's Best In-State Employers here. Media contact. Type of article. Section.
Sethera Therapeutics' polymacrocyclic peptide platform selected for cdmrp-supported Mutant p53 Breast Cancer program. SALT LAKE CITY, UT, UNITED STATES, August 10, 2026 /EINPresswire.com/ - Salt Lake City, UT - August 10th, 2026 - Sethera Therapeutics announced that a collaborative breast cancer research project with Roswell Park Comprehensive Cancer Center has received funding through the Fiscal Year 2025 Breast Cancer Research Program Breakthrough Award, administered by the Congressionally Directed Medical Research Programs (CDMRP). The award supports innovative, high-impact research aimed at advancing the prevention, diagnosis, and treatment of breast cancer. The project reflects CDMRP's commitment to accelerating transformative discoveries that may improve outcomes for individuals affected by breast cancer. The award recognizes the scientific merit, innovation, and collaborative strength of the research teams led by Dr. Katerina Gurova at Roswell Park Comprehensive Cancer Center and Dr. Karsten Eastman at Sethera Therapeutics. Sethera Therapeutics has developed a polymacrocyclic peptide (pMCP) discovery platform designed to discover and engineer constrained peptide molecules with differentiated architectures and chemistries. The technology was first developed at the University of Utah with NIH support and licensed exclusively to Sethera Therapeutics. The pMCP platform offers a new approach for pursuing difficult biological targets that have been challenging for conventional drug modalities. Polymacrocyclic Peptides for Mutant p53-Driven Breast Cancer The collaborative breast cancer project focuses on one of the most common and difficult problems in cancer biology: mutations in p53, a protein often described as the "guardian of the genome." In healthy cells, p53 helps prevent damaged cells from continuing to grow. In many cancers, including aggressive breast cancers, p53 becomes mutated and loses this protective function. These mutant forms of p53 can adopt abnormal conformations that allow cancer cells to survive, divide, and resist treatment. Sethera will use its polymacrocyclic peptide platform to discover constrained peptide molecules that bind mutant p53 and stabilize conformations associated with restored tumor-suppressive activity. Rather than simply blocking a cancer target, the goal is to identify molecules capable of modulating mutant p53 structure and function in ways that are difficult to achieve with conventional modalities. This approach could support a new therapeutic strategy for breast cancers driven by p53 mutations, including forms of the disease that currently have limited targeted treatment options. "This program represents an important external validation of both our platform and our strategy of applying architecture-diverse peptides to targets that have remained beyond the practical reach of many established drug classes," said Karsten Eastman, PhD, CEO of Sethera Therapeutics. "Mutant p53 is an especially compelling test because its biological activity is closely linked to its three-dimensional structure. By working with Dr. Gurova and the Roswell Park team, we can evaluate not only whether our molecules bind mutant p53, but whether they can produce meaningful functional rescue in disease-relevant systems." The Breast Cancer Research Program Breakthrough Award is designed to support promising and innovative studies that challenge existing paradigms and accelerate progress in breast cancer research. The FY25 award underscores the federal government's continued investment in transformative medical research and scientific collaboration. About Sethera Therapeutics Sethera Therapeutics is a biotechnology company developing a polymacrocyclic peptide discovery platform based on enzymatic cross-linking chemistry. The platform enables the generation and screening of highly constrained peptide architectures designed to access chemical and biological space that is difficult to reach with conventional small molecules, biologics, or traditional peptide approaches. Sethera's technology was originally developed at the University of Utah and is exclusively licensed to the company. By collaborating with industry leaders and research institutions, Sethera aims to unlock new possibilities in drug discovery and development for targets that are difficult to address with existing therapeutic modalities. For more information about partnering with Sethera, visit setheratx.com. Karsten Eastman Sethera Therapeutics, Inc. +1 8018504367 email 50 States Today here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. 50 States Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hyundai Hope on Wheels awards $100,000 to Roswell Park to fund CAR t-cell research for children with AML. Thursday, July 23, 2026 - 03:45 pm National nonprofit hits $1 million in lifetime giving to Roswell Park Highlights * Dr. David Byrwa receives $100,000 from Hyundai Hope on Wheels (HHOW). * The grant supports the research of CAR T-cell therapy for children with AML * This marks the tenth grant Roswell Park has received from HHOW. BUFFALO, NY - Hyundai Hope On Wheels(R)(HHOW), a 501(c)(3) nonprofit organization supported by Hyundai Motor America and its U.S. dealers, awarded a $100,000 Hyundai Impact Award Grant to Roswell Park Comprehensive Cancer Center to continue its long-standing commitment to advancing pediatric cancer. The Hyundai Impact Award was presented to David Byrwa, MD, at Roswell Park on Thursday to support research into CAR T-cell therapy for children with relapsed or treatment-resistant acute myeloid leukemia (AML). Dr. Brywa works in the Department of Pediatric Oncology at Roswell Park. 14-year-old Kienen Duggan, a pediatric patient at Roswell Park, shared her cancer story. Kienen was diagnosed with AML last August. She underwent chemotherapy and a bone marrow transplant - with her sister being the donor. "Through it all, I knew I could rely on my doctors here at Roswell Park. One of them was Dr. Dave [Brywa]. He has been there since the beginning," said Kienen. "I always had faith and trust in my doctors at Roswell Park. For every up and down, my doctors were always there rooting for me and cheering me on every step of the way." Keinen has been declared cancer free and rang the Victory Bell at Roswell Park on April 24. This grant through Hyundai Hope on Wheels supports the development of a promising new CAR T-cell therapy for children with limited treatment options. "Our goal is to bring promising discoveries from the laboratory to the children who need them most. This grant allows us to take an important step toward evaluating a new CAR T-cell therapy that has the potential to improve outcomes for pediatric AML patients," said Dr. Byrwa. "Support like this from Hyundai Hope on Wheels makes it possible to move innovative ideas into clinical trials. We're hopeful this research will lead to safer, more effective treatments for children facing relapsed or treatment-resistant AML." With this latest grant, Hyundai Hope on Wheels has reached $1 million in lifetime giving to Roswell Park. "This milestone is a powerful reminder that meaningful progress in pediatric cancer research is built in part through sustained partnerships," said Dr. Kara Kelly, chair of the Department of Pediatric Oncology at Roswell Park. "Hyundai Hope on Wheels' continued investment enables us to ask bigger questions, pursue innovative therapies and, ultimately, give more children the opportunity to live longer, healthier lives." Since 1998, Hyundai Hope on Wheels has worked tirelessly to support the families, researchers, doctors, and children affected by childhood cancer. To date, Hyundai Hope on Wheels has awarded grants totaling more than $303 million, thanks to Hyundai Motor America and its nationwide dealers. Through these partnerships, Hyundai Hope on Wheels continues to advance research and bring hope to families affected by childhood cancer. "Advancing pediatric cancer research requires bold science and sustained commitment," said John Guastaferro, executive director, Hyundai Hope on Wheels. "We are deeply grateful to Roswell Park Comprehensive Cancer Center and its doctors and researchers whose dedication drives progress to the children and families who need it most." About Hyundai Hope on Wheels Hyundai Hope on Wheels(R) is a 501(c)(3) nonprofit organization that is committed to finding a cure for childhood cancer. Launched in 1998, Hyundai Hope on Wheels provides grants to eligible institutions nationwide that are pursuing critical research aimed at improving treatments and saving lives. Hyundai Hope on Wheels is one of the largest nonprofit funders of pediatric cancer research in the country. Primary funding for Hyundai Hope on Wheels comes from Hyundai Motor America and its more than 830 U.S. dealers. In 2025, Hyundai Hope on Wheels awarded over $27 million in pediatric cancer research grants to hospitals throughout the United States. About Hyundai Motor America Hyundai Motor America offers U.S. consumers a technology-rich lineup of cars, SUVs, and electrified vehicles, while supporting Hyundai Motor Company's Progress for Humanity vision. Hyundai has significant operations in the U.S., including its North American headquarters in California, the Hyundai Motor Manufacturing Alabama assembly plant, the all-new Hyundai Motor Group Metaplant America (in development in Georgia), and several cutting-edge R&D facilities. These operations, combined with those of Hyundai's 835 independent dealers, contribute $20.1 billion annually and 190,000 jobs to the U.S. economy, according to a recent economic impact report. For more information, visit www.hyundainews.com. About Roswell Park From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. The Roswell Park team of 4,000+ makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Rated "Exceptional" by the National Cancer Institute, Roswell Park, founded in 1898, was one of the first NCI-designated comprehensive cancer centers in the country and remains the only one in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email [email protected]. About the Roswell Park Alliance Foundation The Roswell Park Alliance Foundation is a is a 501(c)(3) not-for-profit organization that manages all donations made to Roswell Park Comprehensive Cancer Center. Its mission is to maximize dollars available for Roswell Park Comprehensive Cancer Center's most promising lifesaving research, treatment and prevention programs, while supporting the psychosocial needs of patients and families touched by cancer. To learn more about the Roswell Park Alliance Foundation and the research and patient care programs it supports at Roswell Park, visit https://roswellparkalliancefoundation.org/. Media Contact Jackie McDonough, Communications Manager Roswell Park Alliance Foundation [email protected]
Burjeel Medical City, 'Roswell Park' to establish thoracic surgery programme in UAE. WAM 17 Jul 2026, 13:57 GMT+ NEW YORK, 17th July, 2026 (WAM) - Burjeel Medical City (BMC) has entered into a clinical and academic collaboration with New York-based Roswell Park Comprehensive Cancer Centre, a US National Cancer Institute-designated Comprehensive Cancer Centre, to establish a specialised thoracic surgery programme in the UAE. The agreement, which was signed in New York, combines Roswell Park's clinical protocols, multidisciplinary expertise, and academic capabilities with BMC's advanced infrastructure, oncology services, and network. BMC will establish a dedicated thoracic surgery service for cancers affecting the lungs, esophagus, mediastinum, and chest wall. The programme will offer robot-assisted, video-assisted thoracoscopic (VATS), and conventional open procedures based on clinical needs. The programme will be integrated into the multidisciplinary care pathway of Burjeel Cancer Institute (BCI), bringing together thoracic surgery, medical oncology, radiation oncology, pulmonology, pathology, and radiology. Patients will receive coordinated care from diagnosis through surgery, recovery, and follow-up. Thoracic tumour board meetings will allow BMC physicians to review complex cases with Roswell Park specialists. The collaboration will also provide access to Roswell Park faculty for selected reviews and second opinions. Clinical pathways will align with international standards, including National Comprehensive Cancer Network guidelines. Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings, said that this collaboration creates a sustainable pathway for patients in the UAE and across the region to access highly specialised thoracic cancer care closer to home. Dr. Candace S. Johnson, President and CEO of Roswell Park Comprehensive Cancer Centre, said, "Roswell Park has a long-standing commitment to advancing cancer care through collaboration, research, and education." Dr. Sai Yendamuri, Senior Vice President, Chief Strategy Officer and Chair of Thoracic Surgery at Roswell Park Comprehensive Cancer Centre, said: "By working with Burjeel Medical City, we can extend specialised thoracic cancer care expertise, support multidisciplinary decision-making, and help build a world-class programme serving patients across the UAE and the region."